SCHEMBL16670229

SCHEMBL16670229

CCc1c(C(=O)OC)ccn(C2CCN(C(=O)OC(C)(C)C)CC2)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EED O75530 1/20 0.46
RBBP4 Q09028 1/20 0.46
SUZ12 Q15022 1/20 0.46
EZH2 Q15910 1/20 0.46
AEBP2 Q6ZN18 1/20 0.46
ALDH1A1 P00352 2/20 0.43
HCAR1 Q9BXC0 1/20 0.42
TP53 P04637 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN6 P29350 1/20 0.42
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
CTSD P07339 1/20 0.41
CTSE P14091 1/20 0.41
BACE1 P56817 1/20 0.41
GPR119 Q8TDV5 4/20 0.40
MAPT P10636 2/20 0.40
PRKCG P05129 1/20 0.40
PRKCB P05771 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16669964 0.86 EED (0.51) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL16669549 0.85 GPR119 (0.45) ALDH1A1HCAR1TP53PTPN2PTPN1
SCHEMBL27369894 0.81 GPR119 (0.44) ALDH1A1HCAR1TP53PTPN2PTPN1
SCHEMBL30910260 0.78 GPR119 (0.45) ALDH1A1HCAR1TP53PTPN2PTPN1
SCHEMBL21659032 0.78 SRC (0.45) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL16669790 0.77 HCAR1 (0.41) HCAR1TP53KDM4EPKMGPR119
SCHEMBL16669749 0.76 ALDH1A1 (0.46) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL27369897 0.74 GPR119 (0.44) ALDH1A1HCAR1TP53PTPN2PTPN1
SCHEMBL21063603 0.73 POLR1A (0.43) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL16669935 0.73 GPR119 (0.49) ALDH1A1HCAR1TP53PTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3063139-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-11-21 EP disclosed
EP-3063139-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-09-07 EP disclosed
US-9120777-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-01 US disclosed
WO-2015064083-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-07 WO disclosed
US-20150119412-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119412-A1 HETEROCYCLIC COMPOUND SSTR5, SSTR4, SSTR2 EED 4576/4885RBBP4 2960/4885SUZ12 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.